Cargando…
Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study
SIMPLE SUMMARY: We evaluated the efficacy and safety of molecular-targeted therapies (MTTs) in 29 patients who discontinued the combination therapy of nivolumab plus ipilimumab (NIVO+IPI) for advanced or metastatic renal cell carcinoma as real-world outcomes. Patients receiving MTTs had a median fol...
Autores principales: | Iinuma, Koji, Kameyama, Koji, Taniguchi, Tomoki, Kawada, Kei, Ishida, Takashi, Takagi, Kimiaki, Nagai, Shingo, Enomoto, Torai, Tomioka, Masayuki, Kawase, Makoto, Takeuchi, Shinichi, Kato, Daiki, Takai, Manabu, Nakane, Keita, Koie, Takuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559555/ https://www.ncbi.nlm.nih.gov/pubmed/36230501 http://dx.doi.org/10.3390/cancers14194579 |
Ejemplares similares
-
Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
por: Iinuma, Koji, et al.
Publicado: (2021) -
Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2021) -
The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2023) -
Clinical Lymph Node Involvement as a Predictor for Cancer-Specific Survival in Patients with Penile Squamous Cell Cancer
por: Kawase, Makoto, et al.
Publicado: (2022) -
Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2022)